PL2079735T3 - N-(2-hydroksyetylo)-N-metylo-4-(chinolin-8-ylo(1-(tiazol-4-ilometylo)piperydyn-4-ylideno)metylo)benzamid, sposób jego wytwarzania, a także jego zastosowanie do leczenia bólu, lęku i depresji - Google Patents

N-(2-hydroksyetylo)-N-metylo-4-(chinolin-8-ylo(1-(tiazol-4-ilometylo)piperydyn-4-ylideno)metylo)benzamid, sposób jego wytwarzania, a także jego zastosowanie do leczenia bólu, lęku i depresji

Info

Publication number
PL2079735T3
PL2079735T3 PL07835125T PL07835125T PL2079735T3 PL 2079735 T3 PL2079735 T3 PL 2079735T3 PL 07835125 T PL07835125 T PL 07835125T PL 07835125 T PL07835125 T PL 07835125T PL 2079735 T3 PL2079735 T3 PL 2079735T3
Authority
PL
Poland
Prior art keywords
methyl
ylidene
quinolin
thiazol
benzamide
Prior art date
Application number
PL07835125T
Other languages
English (en)
Inventor
Khanh Bui
Cathy Dantzman
Glen Ernst
Valerie Hoesch
Thomas Hudzik
Megan Murphy King
Jie Liu
Jingbo Yan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL2079735T3 publication Critical patent/PL2079735T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
PL07835125T 2006-10-20 2007-10-19 N-(2-hydroksyetylo)-N-metylo-4-(chinolin-8-ylo(1-(tiazol-4-ilometylo)piperydyn-4-ylideno)metylo)benzamid, sposób jego wytwarzania, a także jego zastosowanie do leczenia bólu, lęku i depresji PL2079735T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86232706P 2006-10-20 2006-10-20
EP07835125A EP2079735B1 (en) 2006-10-20 2007-10-19 N- (2 -hydroxyethyl) -n-methyl- 4- (quinolin- 8-yl (1- (thiazol-4- ylmethyl) piperidin- 4 -ylidene) methyl) benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression.
PCT/SE2007/000924 WO2008048171A1 (en) 2006-10-20 2007-10-19 N- (2 -hydroxyethyl) -n-methyl- 4- (quinolin- 8-yl (1- (thiazol-4- ylmethyl) piperidin- 4 -ylidene) methyl) benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression.

Publications (1)

Publication Number Publication Date
PL2079735T3 true PL2079735T3 (pl) 2012-07-31

Family

ID=39314285

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07835125T PL2079735T3 (pl) 2006-10-20 2007-10-19 N-(2-hydroksyetylo)-N-metylo-4-(chinolin-8-ylo(1-(tiazol-4-ilometylo)piperydyn-4-ylideno)metylo)benzamid, sposób jego wytwarzania, a także jego zastosowanie do leczenia bólu, lęku i depresji

Country Status (33)

Country Link
US (2) US7659286B2 (pl)
EP (1) EP2079735B1 (pl)
JP (1) JP4668346B2 (pl)
KR (1) KR20090065534A (pl)
CN (1) CN101528739B (pl)
AR (1) AR063345A1 (pl)
AT (1) ATE543818T1 (pl)
AU (2) AU2007313515B2 (pl)
BR (1) BRPI0717631A2 (pl)
CA (1) CA2667041C (pl)
CL (1) CL2007003009A1 (pl)
CO (1) CO6180450A2 (pl)
CY (1) CY1112718T1 (pl)
DK (1) DK2079735T3 (pl)
ES (1) ES2379519T3 (pl)
HK (1) HK1131556A1 (pl)
HR (1) HRP20120344T1 (pl)
IL (1) IL197876A0 (pl)
MX (1) MX2009003974A (pl)
MY (1) MY148880A (pl)
NO (1) NO20091969L (pl)
NZ (1) NZ577060A (pl)
PE (2) PE20080892A1 (pl)
PL (1) PL2079735T3 (pl)
PT (1) PT2079735E (pl)
RS (1) RS52260B (pl)
RU (1) RU2454414C2 (pl)
SA (1) SA07280549B1 (pl)
SI (1) SI2079735T1 (pl)
TW (1) TW200826939A (pl)
UA (1) UA97648C2 (pl)
UY (1) UY30652A1 (pl)
WO (1) WO2008048171A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0410347A (pt) * 2003-05-16 2006-05-30 Astrazeneca Ab composto, uso de um composto, composição farmacêutica, métodos para as terapias da dor e de distúrbios gostrointestinais funcionais em animal de sangue quente, e, processo para preparação de um composto
MY148880A (en) 2006-10-20 2013-06-14 Astrazeneca Ab N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression
JP2011520956A (ja) * 2008-05-20 2011-07-21 アストラゼネカ・アクチエボラーグ 不安大うつ病性障害を処置する方法
CN101906078B (zh) * 2009-06-08 2012-02-01 上海威智医药科技有限公司 噻唑衍生物的合成方法
CN102106807B (zh) * 2009-12-29 2013-03-27 上海中西制药有限公司 一种固体制剂的制备方法及所得固体制剂
WO2020061165A1 (en) 2018-09-21 2020-03-26 Garland Industries, Inc. Helical hardbanding

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2898339A (en) 1957-07-29 1959-08-04 Wm S Merrell Co N-substituted benzhydrol, benzhydryl, and benzhydrylidene piperidine
US4581171A (en) 1983-07-27 1986-04-08 Janssen Pharmaceutica, N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones useful for treating psychotropic disorders
TW548271B (en) 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
WO1999033806A1 (en) * 1997-12-24 1999-07-08 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(piperidin-4-yl)] aminobenzamides which bind to the delta-opioid receptor
US6492375B2 (en) 1998-06-30 2002-12-10 Neuromed Technologies, Inc. Partially saturated calcium channel blockers
SE9904673D0 (sv) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
MXPA02006137A (es) 1999-12-20 2002-12-05 Neuromed Tech Inc Bloqueadores del canal de calcio parcialmente saturados.
JP2003525938A (ja) * 2000-03-03 2003-09-02 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド ３−（ジアリールメチレン）−８−アザビシクロ［３．２．１］オクタン誘導体
SE0001208D0 (sv) * 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
SE0101768D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
US20040204404A1 (en) 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
SE0300105D0 (sv) * 2003-01-16 2003-01-16 Astrazeneca Ab Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof
SE0301442D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations therof and uses thereof
SE0301444D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0301445D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
BRPI0410347A (pt) 2003-05-16 2006-05-30 Astrazeneca Ab composto, uso de um composto, composição farmacêutica, métodos para as terapias da dor e de distúrbios gostrointestinais funcionais em animal de sangue quente, e, processo para preparação de um composto
SE0301441D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0400025D0 (sv) * 2004-01-09 2004-01-09 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
WO2005087742A1 (en) 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
MY148880A (en) 2006-10-20 2013-06-14 Astrazeneca Ab N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression

Also Published As

Publication number Publication date
US20080182875A1 (en) 2008-07-31
US7977355B2 (en) 2011-07-12
PE20140634A1 (es) 2014-06-19
AU2007313515A1 (en) 2008-04-24
MX2009003974A (es) 2009-04-27
RS52260B (en) 2012-10-31
HRP20120344T1 (hr) 2012-05-31
CA2667041A1 (en) 2008-04-24
US7659286B2 (en) 2010-02-09
PT2079735E (pt) 2012-05-07
JP2010506910A (ja) 2010-03-04
AU2010226996A1 (en) 2010-10-28
NZ577060A (en) 2011-01-28
CA2667041C (en) 2011-09-06
KR20090065534A (ko) 2009-06-22
AU2007313515B2 (en) 2010-11-25
ATE543818T1 (de) 2012-02-15
CL2007003009A1 (es) 2008-06-06
CN101528739A (zh) 2009-09-09
HK1131556A1 (pl) 2010-01-29
JP4668346B2 (ja) 2011-04-13
IL197876A0 (en) 2009-12-24
SI2079735T1 (sl) 2012-05-31
TW200826939A (en) 2008-07-01
PE20080892A1 (es) 2008-09-11
CY1112718T1 (el) 2016-02-10
NO20091969L (no) 2009-05-20
CN101528739B (zh) 2011-11-30
RU2009111337A (ru) 2010-11-27
AR063345A1 (es) 2009-01-21
RU2454414C2 (ru) 2012-06-27
EP2079735B1 (en) 2012-02-01
CO6180450A2 (es) 2010-07-19
UA97648C2 (ru) 2012-03-12
UY30652A1 (es) 2008-05-31
ES2379519T3 (es) 2012-04-26
SA07280549B1 (ar) 2010-09-29
US20100160374A1 (en) 2010-06-24
WO2008048171A1 (en) 2008-04-24
BRPI0717631A2 (pt) 2013-10-29
EP2079735A4 (en) 2010-12-29
MY148880A (en) 2013-06-14
EP2079735A1 (en) 2009-07-22
DK2079735T3 (da) 2012-05-21

Similar Documents

Publication Publication Date Title
IL197161A (en) Derivatives 4- (n-azacycloalkyl) anilides Preparations containing and using them
SI2182949T1 (sl) (2S,3R)-N-(2-((3-piridinil)metil)-1-azabiciklo(2.2.2)okt-3-il)benzofuran -2-karboksamid, nove oblike soli in postopki za njihovo uporabo
IL185785A0 (en) Certain substituted amides, method of making, and method of use thereof
ZA200804030B (en) Improved process for the preparation of 4-(benzimidazolylmethylamino)benzamides and the salts thereof
DE602006020327D1 (de) 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-aminder-hemmer zur behandlung thromboembolischer erkrankungen
IL184722A0 (en) Novel haloalkylsulfonanilide derivative, herbicide, and method of use thereof
ZA200901633B (en) Certain substituted amides, method of making, and method of use thereof
IL197264A0 (en) Certain substituted amides, method of making, and method of use thereof
EP1874286A4 (en) METHOD AND COMPOSITIONS FOR TREATING ANXIETY STATE
TWI365866B (en) Amide derivatives, process for preparation thereof and use thereof as insecticide
HK1166983A1 (zh) 包含用於治療疾病或紊亂的化合物的固體形式，其組合物，及其用途
HK1081945A1 (en) Process for the synthesis of 4,5-dimethoxy-1-(methylaminomethyl)-benzocy clobutane, and the use thereof
EP1641748A4 (en) INHIBITORS OF BETA-SECRETASE BASED ON N-ALKYL PHENYLCARBOXAMIDE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
DK1768833T3 (da) Formlegeme, fremgangsmåde til dets fremstilling samt dets anvendelse
IL197876A0 (en) N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression
JO3440B1 (ar) استخدام الأغوميلاتين في تحضير علاجات لمداولة اضطرابات القلق العام.
EP1934140A4 (en) SILICA NANOBOITIERS AND METHODS OF ELEMENTS AND USES THEREOF
IL186049A0 (en) Prophylactic or therapeutic agent for depression or anxiety disorders
BRPI0614481A2 (pt) composto, composição farmecêutica, uso do composto, e, método de tratamento de distúrbios mediados por mglur5
HK1171010A1 (en) 4-(1,2,4-dioxazol-3-yl)benzamides for the treatment of diabetes and obesity 4-(124--3-)
IL199239A0 (en) Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy)-3-bromo-6-
ITRM20050478A1 (it) Apparato per l'applicazione contemporanea della carbossiterapia e della mesoterapia.
IL186373A0 (en) Use of agomelatine for obtaining medicaments used for treating bipolar disorders
ZA200809565B (en) 4-(2, e-dichloro-benzoylamino)-1H-pyrazole-s-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide for the treatment of cancer
DK1926717T3 (da) Fremgangsmåde til fremstilling af 3,4-dichlor-N-(2-cyano-phenyl)-5-isothiazolcarboxamid